Analysis of the Incidence of Expression of Tumor Antigens MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer in Asiatic Patients
This study will be based upon the analysis of samples and patient-related data already
available at the various investigation sites. There will be no study treatment and no
study-specific procedure carried out on the patients.
Clinical data collected will include patient demographics (age, gender), Tumor, Node,
Metastasis (staging system) [TNM stage], histopathologic description and the patient smoker
status. Strict anonymity of patient data will be maintained.
This retrospective study is based upon the analysis of archived formalin-fixed
paraffin-embedded tissue samples and patient-related data already available at the
Observational Model: Cohort, Time Perspective: Retrospective
Determination of the expression of MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME antigens in tumor tissue from Asiatic patients with pathologically proven stage I, II or III NSCLC (as defined by the International Staging System).
Up to 6 months approximately.
GSK Clinical Trials
Taiwan: Taiwan Food and Drug Administration (TFDA)